VA
JSPR icon

Verdad Advisers’s Jasper Therapeutics JSPR Stock Holding History

Verdad Advisers’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-73,967
Closed -$64.8K – 246
2026
Q1 		$64.8K Buy
+73,967
New +$103K 0.07% 167

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verdad Advisers's JSPR Position: Q2 2026 in Review

Verdad Advisers sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 73,967 shares — an estimated $64.8K sold.

Verdad Advisers first reported a position in JSPR in Q1 2026 and held it in 1 quarter. The position peaked at $64.8K in Q1 2026. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Verdad Advisers reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Verdad Advisers sold 73,967 Jasper Therapeutics shares in Q2 2026, an estimated $64.8K.
  • Verdad Advisers first reported a position in Jasper Therapeutics in Q1 2026 and held it in 1 quarter.
  • Verdad Advisers's Jasper Therapeutics position peaked at $64.8K in Q1 2026.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.